What Happened?
Boston, MA-based Inform Genomics has Appointed Carl de Moor as Chief Technology Officer
About the Company
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.
About the Person
Dr de Moor has more than 25 years of experience in epidemiology, biostatistics, and health outcomes research. His areas of expertise include pharmacoepidemiologic study designs and methods, PRO (patient reported outcome) assessment and analysis, predictive modeling, longitudinal and time varying modeling, correlated data methods, and multivariate methods. Prior to joining Inform Genomics, Dr de Moor was senior principal epidemiology and lead, Epidemiology Center of Excellence, at IMS Health, where he designed and directed retrospective epidemiologic research. He has served in several executive roles in industry, including vice president of epidemiology at Mapi, a late-phase Clinical Research Organization (CRO); executive director, Epidemiology and Health Outcomes, at PPD, Inc; and vice president of Health Outcomes and Pharmacoeconomics at Supportive Oncology Services, Inc, an oncology CRO. In these roles he led observational outcomes research and was responsible for scientific oversight, study design development, statistical analysis planning and conduct, and economic modeling. In addition to his industry experience, Dr de Moor has held faculty positions as associate professor at Harvard Medical School, Boston, Massachusetts, and at The University of Texas (UT) MD Anderson Cancer Center, Houston, and as research assistant professor in the Division of Hematology/Oncology at UT Health Science Center at San Antonio. In these positions, he designed and analyzed phase 1, phase 2, and phase 3 clinical trials, as well as registries and other observational research, including predictive modeling in cancer patients. Dr de Moor has published more than 100 peer-reviewed papers and has been a co-investigator in more than 40 National Institutes of Health grants. He is currently on the editorial board of the journal Drugs in Context and is research professor in the College of Health and Human Services at The University of North Carolina at Charlotte. Dr de Moor received his bachelor of science degree in biology from San Diego State University, San Diego, California, and his doctoral degree in biostatistics from the University of Washington, Seattle, Washington.
Info Source
News
Short Profile